Determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection.
ICU admission
SARS-CoV-2
Viral shedding
steroids
tocilizumab
Journal
Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
23
11
2020
revised:
30
01
2021
accepted:
09
02
2021
pubmed:
28
2
2021
medline:
19
5
2021
entrez:
27
2
2021
Statut:
ppublish
Résumé
To evaluate determinants of prolonged viral RNA shedding in hospitalized patients with SARS-CoV-2 infection. Hospitalized patients with SARS-CoV-2 positive nasopharyngeal RT-PCR were included in a single-center, retrospective study. Patients were divided in 2 groups according to the timing of viral clearance [≤14 days, "early clearance (EC)" and >14 days, "late clearance (LC)"]. 179 patients were included in the study (101 EC, 78 LC), with median age 62 years. Median time of viral shedding was 14 days (EC/LC 10 and 19 days, respectively, P < 0.0001). Univariate analyses showed that age, male gender, receiving corticosteroids, receiving tocilizumab, ICU admission, low albumin and NLR ratio were associated with late viral clearance. In the multivariable analysis, older age (P = 0.016), albumin level (P = 0.048), corticosteroids (P = 0.021), and tocilizumab (P = 0.015) were significantly associated with late viral clearance. Age, albumin, tocilizumab and corticosteroid treatment were independently associated with a prolonged SARS-CoV-2 RNA shedding.
Identifiants
pubmed: 33639375
pii: S0732-8893(21)00040-7
doi: 10.1016/j.diagmicrobio.2021.115347
pmc: PMC7879029
pii:
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
115347Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Références
J Clin Virol. 2004 Dec;31(4):304-9
pubmed: 15494274
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Med Virol. 2020 Oct;92(10):2227-2231
pubmed: 32484958
Ann Intensive Care. 2013 Feb 15;3(1):4
pubmed: 23414610
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Lancet Infect Dis. 2020 Jun;20(6):656-657
pubmed: 32199493
J Med Virol. 2020 Nov;92(11):2666-2674
pubmed: 32492211
Clin Chim Acta. 2009 May;403(1-2):23-30
pubmed: 19141296
Sci Total Environ. 2020 Aug 1;728:138812
pubmed: 32335406
Ann Intensive Care. 2020 May 24;10(1):63
pubmed: 32449091
Eur Respir J. 2020 Jul 16;56(1):
pubmed: 32430428
J Transl Med. 2020 Apr 14;18(1):164
pubmed: 32290839
Lab Invest. 2018 Sep;98(9):1237-1249
pubmed: 29884907
Infect Dis Health. 2020 Aug;25(3):210-215
pubmed: 32473952
Nat Commun. 2021 Jan 11;12(1):267
pubmed: 33431879
Eur Respir J. 2020 Jul 2;56(1):
pubmed: 32398298
Clin Infect Dis. 2005 Nov 15;41 Suppl 7:S504-12
pubmed: 16237654
Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1091-105
pubmed: 15306395
Int J Antimicrob Agents. 2020 Aug;56(2):106029
pubmed: 32454071
Chest. 2020 Nov;158(5):1876-1884
pubmed: 32569635
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Med J Aust. 2020 May;212(9):416-420
pubmed: 32266987
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209381
Lancet Microbe. 2021 Jan;2(1):e13-e22
pubmed: 33521734
Quant Imaging Med Surg. 2020 May;10(5):1141-1144
pubmed: 32489935
Circ Res. 2020 Jul 17;127(3):400-401
pubmed: 32508261
Antioxid Redox Signal. 2021 Jul 10;35(2):139-142
pubmed: 32524832
J Infect Dis. 2009 Aug 15;200(4):492-500
pubmed: 19591575
Hum Reprod Update. 2005 Jul-Aug;11(4):411-23
pubmed: 15817524
Arthritis Rheum. 2011 May;63(5):1255-64
pubmed: 21305508
Clin Infect Dis. 2020 Jul 28;71(15):799-806
pubmed: 32271376
J Infect Dis. 2020 Aug 17;222(6):910-918
pubmed: 32614392
Chin Med J (Engl). 2020 May 5;133(9):1039-1043
pubmed: 32118639
Emerg Infect Dis. 2004 Oct;10(10):1841-3
pubmed: 15504274
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
J Clin Virol. 2020 Aug;129:104477
pubmed: 32505778
Arterioscler Thromb Vasc Biol. 2012 Jun;32(6):1392-9
pubmed: 22460555